Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway

Background: We aimed to investigate the effect of probiotic VSL#3 on NF-kappa B and TNF-alpha in rats with colitis and the correlation with TLR4-NF-kappa B signal pathway. Methods: Sixty Sprague Dawley (SD) rats were divided into the control, model and therapy groups (n=20) according to the random number table. Rats in the model and therapy groups were modeled for colitis, and rats in the therapy group were intragastrically administered with probiotic VSL#3. The expression of TLR4 and NF-kappa B protein, and the levels of NF-kappa B, TLR4, and TNF-alpha mRNA in the colon tissue were detected. The concentration of TNF-alpha in the serum after modeling but before intragastric administration (T0), 3d (T1) and 7d after intragastric administration (T2) was detected. Results: The expression of TLR4 and NF-kappa B p65 protein, and the levels of TLR4, NF-kappa B, and TNF-alpha mRAN in the therapy group decreased (P < 0.001). At T0, T1, and T2, the concentration of TNF-alpha in the model and control groups increased (P < 0.001). TLR4 and NF-kappa B in the therapy group were positively correlated with TNF-alpha mRAN (P < 0.050). Conclusion: In conclusion, probiotic VSL#3 inhibits the expression of NF-kappa B and TNF-alpha in rats with colitis through TLR4-NF-kappa B signal pathway, so it is expected to be a first choice drug for the treatment of colitis. Conclusion: In conclusion, probiotic VSL#3 inhibits the expression of NF-kappa B and TNF-alpha in rats with colitis through TLR4-NF-kappa B signal pathway, so it is expected to be a first choice drug for the treatment of colitis.